Vitamin D fluctuations and the mucosal immune response
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 3R01AT005378-10S1
Grant search
Key facts
Disease
COVID-19Start & end year
20092021Known Financial Commitments (USD)
$240,750Funder
National Institutes of Health (NIH)Principal Investigator
Margherita T CantornaResearch Location
United States of AmericaLead Research Institution
Pennsylvania State University-Univ ParkResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Disease pathogenesis
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Summary: Vitamin D supplements have been suggested as being useful in high doses for preventing and treating severe disease associated with SARS-CoV-2 infection (i.e. COVID-19). Vitamin D status has been shown to be low in patients with acute respiratory infections. Unfortunately, it is yet unclear whether those associations are causal. Currently, the mechanisms underlying the effects of vitamin D in the lung are not completely understood. In addition, there is not data that demonstrates that vitamin D or the active form of vitamin D (1,25(OH)2D, 1,25D) is effective for improving outcomes following a viral infection. The effects and timing of supplemental vitamin D will be tested on host resistance to SARS-CoV-2 infection in mice and hamsters. The basic mechanisms by which vitamin D regulates the immune response following a respiratory virus infection are critical for the safe and effective messaging for vitamin D supplementation. Understanding the mechanisms underlying the effects of vitamin D in the lung is needed to provide responsible guidance on whether it is safe and effective to supplement individuals with high amounts of vitamin D to protect from COVID-19 disease.